Experimental studying of the drug efficiency Prostamax in the therapy of chronic aseptic prostatitis and its complications

Tatyana Gennadyevna Borovskaya, Angelina Vladimirovna Pakhomova, Anna Vladimirovna Vychuzhanina, Marina Evgenyevna Poluektova, Tatyana Ivanovna Fomina, Lubov Aexandrovna Ermolaeva, Juliya Aexandrovna Schemerova, Oleg Konstantinovich Granstrem, Evgeniy Anatolyevich Neplochov

.
Research Studies Institute of Pharmacology SO, The Russian Academy of Medical Science, Tomsk, Russia.

DOI: 10.4236/mri.2013.23007                

Abstract

The treatment of one of the most common urological diseases, a chronic aseptic prostatitis, is an exigeant problem. Used methods of pharmacotherapy are insufficiently effective and after treatment, as a rule, there comes a recrudescence. The efficiency of new prostatotropic agent Prostamax is studied in the present work, this drug is related to bioregulator peptides at experimental chronic aseptic inflammation of prostate gland. It is established that Prostamax reduces intensity of signs of a chronic inflammation (swelling, hyperemia of vessels, lymphoid infiltration), prevents development of sclerotic and atrophic processes. It is shown that the agent intensifies sexual activity of animals. Efficiency of the preparation Prostamax surpasses that among widespread prostatotropic agents derived from the extract of Serenoa repens and prostate of animals.

Keywords

Chronic Aseptic Prostatitis; Prostamax; Rats

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Krieger, J.N., Lee, S.W., Jeon, J., Cheah, P.Y., et al. (2008) Epidemiology of prostatitis. International Journal of Antimicrobial Agents, 31, 85-90. doi:10.1016/j.ijantimicag.2007.08.028
[2]	Batstone, G.R. and Doble, A. (2003) Chronic prostatitis. Current Opinion in Urology, 13, 23-29. doi:10.1097/00042307-200301000-00005
[3]	Krieger, J.N., Nyberg, L.J. and Nickel, J.C. (1999) NIH consensus definition and classification of prostatitis. JAMA, 282, 236-237. doi:10.1001/jama.282.3.236
[4]	Wenninger, K., Heiman, J.R., Rothman, I., Berghuis, J.P. and Berger, R.E. (1996) Sickness impact of chronic nonbacterial prostatitis and its correlates. Journal of Urology, 155, 965-968. doi:10.1016/S0022-5347(01)66359-6
[5]	Iunda, I.F. and Varvashenia, V.V. (1993) Sexual disorders in patients with prostatic adenoma combined with chronic prostatitis and without. Lik Sprava, 10-12, 47-51.
[6]	Lowe, F.C. and Ku, J.C. (1996) Phytotherapy in treatment of bening prostatic hyperplasia: A critical review. Urology, 48, 12-20. doi:10.1016/S0090-4295(96)00077-5
[7]	Gorpichenko, I.I. and Boyko, N.I. (1993) Administration of the peptidic bioregulator—Prostatilen in the sexological and urological practice. Andrology Reproduction Sexology, 2, 4-7.
[8]	Kamalov, А.А. and Dorofeev, S.D. (2003) The modern views according to the problem of chronic prostatitis. Russian Medical Journal, 11, 229-233.
[9]	Havinson, V.H. and Malinin, V.V. (2008) Heroprotective effect of peptides in the case of health disorders due to ecological factors. Reporter of the Russian Military Medical Academy Appendix, 2-3, 472.
[10]	Borovskaya, T.G., Fomina, T.I. and Loskutova, О.P. (2002) Antibodies to a prostatic specific antigene in over small doses: Influence on a morphological and functional conditions of prostate gland of rats. Bulletin of Experimental Biology and Medicine, A, 104-106.
[11]	Bayne, C.W., Ross, M., Donnelly, F. and Habib, F.K. (2000) The selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) on the prostate. Journal of Urology (Baltimore), 164, 876-881.
[12]	Reissigl, A., Pointner, J., Djavan, B., et al. (2003) Multi centre study to evaluate the safety and efficacy of phytotherapeuticum Permixon in the treatment of chronic prostatitis/chronic pelvic pain syndrome. Materials of 18th EAU Meeting, Madrid, 49.
[13]	Vela-Navarrete, R., Garcia-Cardoso, J., Barat, A., Manzerbeitia, F., et al. (2002) Effects of the lipido sterolic extract of Serenoa repens (Permixon) on infiltrating cells and inflammatory markers in prostatic tissues from BPH patients. Materials of 17th EAU Meeting, Birmingham, A-238.
[14]	Tkachuk, V.N., Al-Shukri, S.K. and Lotsan-Medvedev, A.K. (2006) Vitaprost efficacy in patients with chronic abacterial prostatitis. Urologia, 2, 71-75.
[15]	Mitropoulos, D., Kyroudi, A., Zervas, A. et al. (2002). In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cell accumulation and glandular epithelium trophism in the rat prostate. World Journal of Urology, 19, 457-461.
[16]	Saveleva, K.V., Borovskaya, T.G., Hejfets, I.A., et al. (2007) Comparative estimation of pharmacological activity Afala on model harmone productive inflammations of prostate at rats. Bulletin of Experimental Biology and Medicine, 144, 542-544.
[17]	Sivkov, А.V., Oshchepkov, V.N. and Medvedev, А.M. (2005) Diseases of prostate gland. The first results of the administration of lipidic sterolic extract of Serenoa repens of patients with chronic abacterial prostatitis. Consilium Medicum, 7. http://www.consilium-medicum.com/medicum/article/12932/